Stockscreener 앱 받기
0.545
4.80%
-0.0275
시간 외 거래:
.46
-0.085
-15.60%
전일 마감가:
$0.5725
열려 있는:
$0.58
하루 거래량:
1.32M
Relative Volume:
0.51
시가총액:
$21.53M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-0.406
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
+7.92%
1개월 성능:
-22.57%
6개월 성능:
-80.94%
1년 성능:
-80.11%
1일 변동 폭
$0.533
$0.58
1주일 범위
$0.5037
$0.5992
52주 변동 폭
$0.5028
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.545 | 22.61M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-12-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis - Investing.com India
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq
Vistagen (VTGN) Surpasses Revenue Expectations in Q3 - GuruFocus
Vistagen Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
R&D-driven loss at Vistagen (Nasdaq: VTGN) as PALISADE-4 Phase 3 advances - Stock Titan
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update - FinancialContent
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. Investors of a Class Action Lawsuit and ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen - GlobeNewswire
Investors who lost money with shares of Vistagen Therapeutics, - openPR.com
VTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - The Malaysian Reserve
LEVI & KORSINSKY, LLP ANNOUNCES SECURITIES CLASS ACTION FILED AGAINST VISTAGEN THERAPEUTICS UNDER FEDERAL SECURITIES LAWS - PR Newswire
Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2026 Result - GuruFocus
Gap Down: Will Vistagen Therapeutics Inc outperform during market ralliesJuly 2025 Weekly Recap & Daily Momentum Trading Reports - baoquankhu1.vn
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Vistagen Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
Vistagen Therapeutics Securities Litigation: When Clinical Optimism Meets Disclosure Duty - TipRanks
VistaGen’s PALISADE-3 trial fails primary endpoint in SAD - MSN
VistaGen Receives Nasdaq Notice on Minimum Bid Compliance - TipRanks
Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VTGN Investors Encouraged to Seek Lead Plaintiff Role in - GlobeNewswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - accessnewswire.com
VTGN Investor Alert: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026 - PR Newswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - marketscreener.com
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) - GlobeNewswire
Investors who lost money on Vistagen Therapeutics, Inc.(VTGN) should contact The Gross Law Firm about pending Class ActionVTGN - ChartMill
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
March 16, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTGN - The Malaysian Reserve
VTGN INVESTOR ALERTLEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS - The Malaysian Reserve
VTGN CLASS ACTION ALERT: Robbins LLP Urges Vistagen Therapeutics, Inc. Stockholders to Reach Out for Information About the Securities Class Action Lawsuit - The Malaysian Reserve
VTGN CLASS ACTION ALERT: Robbins LLP Urges Vistagen Therapeutics - GuruFocus
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding The Upcoming Lead Plaintiff Deadline for the Filed Class Action Lawsuit - GlobeNewswire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Vistagen - GlobeNewswire
Vistagen Faces Securities Litigation Investigation - Intellectia AI
Vistagen Faces Class Action Lawsuit Impacting Stock Price - intellectia.ai
VTGN INVESTOR ALERT -- LEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS - Sahm
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026 - marketscreener.com
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lead Plaintiff Deadline of March 16, 2026 in the Vistagen - GlobeNewswire
2026-02-04 | VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):